Skip Ribbon Commands
Skip to main content
Skip to main navigation Skip to main content
Sign In

 Index

Section:

​​​​A PDF copy of the Code is available on this website and can be searched using any term.

Key

numbers refer to clauses in the Codes

​si refers to supplementary information to a clause in the Code

¶ followed by number refers to a paragraph in the Constitution and Procedure

A

abbreviated advertisements – 5
ABPI (the Association of the British Pharmaceutical
Industry)
     Board of Management – ¶ 1.3, ¶ 3.1, ¶ 11.4, ¶ 12, ¶ 13.4, ¶ 16.1 & ¶ 16.6
     examinations – 16.3 & si
absolute risk, reference to – si to 7.2
administrative charges
     appeals against number of – ¶ 16.5
     determination of charges
          in cases – ¶ 16.5
          in relation to voluntary admissions – ¶ 16.4
          in co-promotion – ¶ 16.3
          levels of – ¶ 16.2
     ​​failure to pay – ¶ 16.6
     payment of in relation to rulings          
          by Appeal Board – ¶ 10.1 & ¶ 10.2
          by Panel – ¶ 7.1 & ¶ 7.2
advance notification of new products – si to 3.1
adverse reactions
     claims about – 7.9
     need to consult SPC – 4.2 & 5.4
     references to in prescribing information – 4.2
     reporting mechanisms – 4.9 & si, 5.6, 5.7 & si
     reports from representatives – 15.6
advertising to the public – 1.1 & 26.1 & si
advice on Code – ¶ 18.1
advice on personal medical matters – si to 26.4
all-embracing claims – 7.10 & si
amendments to Code and Constitution and Procedure– ¶ 19
amount of advertising in journals – 6 & si
animal data, use of – si to 7.2
annual report – ¶ 20
appeals against Panel rulings
     appeals by complainants – ¶ 7.3 & ¶ 7.4
     appeals by respondent companies – ¶ 7.3 & ¶ 7.5
     appearance before Appeal Board – ¶ 4.6
     withdrawal of appeals – ¶ 15
Appeal Board –
see Code of Practice Appeal Board
     applicability of codes – 1.11 & si
     approval of promotional material – see certification
artwork, illustrations, graphs and tables – 7.8
     abbreviated advertisements – si to 5.4, 5.5, 5.6, 5.7, 5.8 & 5.9
     references to sources when taken from published studies – 7.8 & si
     see also si to 7.2 on use of statistical information
audio-visual material and interactive data systems etc
     abbreviated advertisements not permitted – 5.2
     certification – si to 14.1
     prescribing information requirements – 4.4 & si, 4.5 & si & 4.6
audit of company’s procedures – ¶ 10.4, ¶ 11.3 & ¶ 12.2
     charges for – ¶ 16.1
automated calling systems – 9.9

Back to top

B

benefit/risk profile – si to 7.10
benefits, personal – 18.1 & si & 19.1 & 19.2 & si
black triangle symbol – 4.10 & si and si to 4.1
     in abbreviated advertisements – 5.7 & si
     in material intended for patients – 26.3 & si
Blue Guide – si to 1.1 & 28.1, 28.4 & 28.5 & page 60
bonus stock – see samples – si to 17
brand names, use of other companies’ – si to 7.3
Bribery Act – page 60 

briefing material for representatives – 15.9 & si 

British Medical Association
     case reports – ¶ 13.5
     consultation with regarding:
          independent Appeal Board members – ¶ 3.2
          the Code – ¶ 19.2

Back to top

C

carers, hospitality to – si to 27.2
case preparation manager – ¶ 2.1, ¶ 5.1, ¶ 5.2, & ¶ 5.6
case reports – ¶ 13
central platform for disclosure of transfers of value – si to 24.1 (see also disclosure of transfers of value)
certification
     general – 14
     audio and audio-visual material etc – si to 14.1
     content of certificate – 14.5
     digital material – si to 14.1
     educational material relating to diseases
          or medicines – 14.3
     Internet – si to 14.1

     joint ventures and co-promotion – si to 14.1
     joint working material – 14.3, see also si to 20
     meetings held outside UK – 14.2 & si
     non-promotional material relating to the provision
     of medical and educational goods and services
     – 14.3
     notification of signatories – 14.4
     patient organisation material – 14.3
     patient support programme material – 14.3
     presentations by UK speakers at meetings held
     outside the UK – si to 14.2
     preservation of certificates – 14.6 & si
     promotional aids – si to 14.1
     promotional material – 14.1
     promotional material at international conferences in
     UK – si to 3
     signatories, qualifications and experience of – 14.1
     & si
children in advertisements – si to 7.8
clinical and scientific opinion
     current views of authors – 10.4 & si
     disparaging clinical and scientific opinion – 8.2
     emerging opinion – si to 7.2
clinical assessments – 12.2 clinical trial data, use of – si to 7.5
clinical trials, disclosure of details – 13.1 & si
Codes of Practice for Advertising Over-the-Counter    
     Medicines of the PAGB – page 60
Code of Practice Appeal Board
     Constitution and Procedure – ¶ 3 & ¶ 4
     co-option to – ¶ 4.2
     independent members to be in a majority – ¶ 4.2
     membership – ¶ 3.2
     power to:
          publicly reprimand – ¶ 10.5 & ¶ 11.3
          require audit – ¶ 10.4 & ¶ 11.3
          require a corrective statement – ¶ 10.6 & ¶ 11.3
          require pre-vetting – ¶ 10.4 & ¶ 11.3
          require recovery of items – ¶ 10.3 & ¶ 11.3
     reports from Code of Practice Panel – ¶ 4.1 & ¶ 8
     reports to ABPI Board – ¶ 12.1
     reports to, consideration of – ¶ 11
     rulings – ¶ 10
Code of Practice levy – ¶ 16.1
Code of Practice Panel
     Constitution and Procedure – ¶ 2
     membership – ¶ 2.1
     power to suspend advertising on complaints from
          Medicines and Healthcare products Regulatory
          Agency – ¶ 9.2
     power to suspend material/activities pending an
          appeal – ¶ 7.1
     reports to Appeal Board – ¶ 8
     rulings – ¶ 7
Commission on Human Medicines, Medicines and Healthcare products Regulatory Agency and licensing authority, references to – 9.5 & si
comparisons
     general – 7.2 & 7.3 & si
     disparaging references, prohibition on – 8.1 & si     
     hanging comparisons – si to 7.2
     price/cost comparisons – si to 7.2
Competition and Markets Authority
     consultation with on Code – ¶ 19.2
competitions & quizzes – si to 18.1
complaints procedure
     complaints arising from media criticism – ¶ 6
     complaints from Medicines and Healthcare products
          Regulatory Agency – ¶ 9
     confidentiality of complainants – see introduction to
     Constitution and Procedure – page 42
     dealing with complaints – ¶ 5 to ¶ 13
     making complaints
          general – see introduction to Constitution and Procedure – page 42
          by pharmaceutical companies – ¶ 5.3
     withdrawal of complaints – ¶ 15
conciliation between companies – ¶ 18.2
conferences – see meetings
confidence in the industry – 2 & si, see also ¶ 13.7
consultants
     disclosure of payments to – 23.2 & 23.3 & si
     from patient organisations – 27.8 & si
     use of – 23 & si
continuing professional development meetings and
     courses – si to 22.1
contracts with institutions etc – 21
co-promotion – si to 14.1
corporate advertising, examination of – si to 14.3
cost comparisons – si to 7.2
cost of promotional material – 9.7
criticism in media – ¶ 6
current views of authors – 10.4 & si

Back to top

D

data on file, provision of – 7.7
date of prescribing information – 4.2 & si
date of promotional material – 4.8
delivery of items by representatives – si to 15.3
devices – si to 4.1
disclosure of transfers of value – 1.10 & si & 24 & si
discounts – see trade practices
discredit to the industry – 2 & si & ¶ 13.7
disease awareness campaigns – si to 26.2      
    Disease Awareness Campaigns Guidelines – si to    
    26.2 & page 60
disguised promotion – 12 & si
disparaging references – 8 & si
distribution of promotional material – 11 & si
doctors, use of names and photographs – 9.3
donations
     in lieu of hospitality – si to 15.3
     to charities – si to 15.3 & 18.1
     to individuals – si to 19.2
     to institutions etc – 19.1 & 19.2 & si
     see also prohibition on financial inducements – 18.1
DVDs for health professessionals – si to 18.1
dynamic content for websites – si to 14.1

Back to top

E

economic evaluation of medicines – si to 7.2
educational goods and services – 19 & si
educational or informational material – 9.7
EFPIA Code of Practice on Relationships between the
Pharmaceutical Industry and Patient Organisations –
see introduction to Code & page 60
EFPIA Code on Disclosure of Transfers of Value by
Pharmaceutical Companies to Healthcare Professionals
and Healthcare Organisations – see introduction to Code
& page 60
EFPIA Code on the Promotion of Prescription–only
     Medicines to, and Interactions with, Healthcare
     Professionals – see introduction to Code & page 60
electronic data communications – 9.9
email – 9.9 & si & si to 15
emoticons – si to 9.1 & 9.2
employee responsible for ensuring compliance with
Code – 1.12 & si
employees, current and prospective, information for –
si to 26.2
envelopes – 9.8
Europe – definition – si to 24.1
European Directive – see introduction to Code & page 60
exaggerated or all-embracing claims – 7.10 & si
examination of material – si to 14.3
examinations for representatives – 16.3 to 16.4 & si
exemptions to promotion – 1.2 under ‘It does not include
exhibitions and exhibition panels, prescribing
information requirements – si to 4.1
experience programmes – 12.2
exposed mailings – 9.8

Back to top

F

facsimile, use of – 9.9 & si to 15
films – see audio-visual material and interactive
     data systems etc
financial inducements, prohibition of – 18.1
financial information – si to 26.2
format & size of promotional material – 9.7 & si – see
also si to 11.2
free goods – see samples – si to 17
frequency
     of calls by representatives – 15.4 & si
     of mailings – 11.2 & si
     of mailings for new medicines – si to 11.2

Back to top

G

General Medical Council – si to 15.3, 18.1 & 22.1 &
page 60
General Pharmaceutical Council – si to 15.3, 18.1 & 22.1
& page 60
gifts – 18.1 & si
grants to institutions etc – 19.1 & 19.2 & si
graphs – see artwork, illustrations, graphs and tables
guidelines on company procedures relating to the Code
     of Practice – page 53

Back to top

H

hanging comparisons – si to 7.2
health professional
     definition – 1.4
     use of name and photograph – 9.3
health professionals’ code of conduct – si 15.3, 18.1 &
22.1 and page 60
health professions, criticism of – 8.2
health technology assessments – 1.2 under It does not include & si to 26.2
healthcare organisation – definition – 1.9 & si
healthy volunteer studies, use of data from – si to 7.2
high standards, maintenance of – 9.1
hospitality – 22
     excessive – si to 2, see also ¶ 13.7
     limit on cost of meal – 22.2 & si
Human Medicines Regulations – see introduction to Code
& page 60

Back to top

I

IFPMA Code of Practice – see introduction to Code
& page 60
illustrations
     see artwork, illustrations, graphs and tables
inducements – 18.1 and si to 2, see also ¶ 13.7
information to the public – 26 & si, 28 & si
informational or educational materials – 9.7
inserts in journals
     cannot be abbreviated advertisements – 5.2
     size of – 6.2
     see also si to 6.3
interactive data systems
     see audio-visual material and interactive data
     systems etc
international conferences, symposia and meetings
     see meetings
international journals, advertising in – si to 1.1
Internet
     general – 28
     abbreviated advertisements not permitted – 5.2
     access to promotional material by public – si to 28.1
     certification – si to 14.1
     journals – 28.4
     prescribing information requirements – 4.6
in-vitro data – si to 7.2
items delivered by representatives – si to 15.3
items for patients – 18.2 & si

Back to top

J

joint ventures & co-promotion – si to 14.1
joint working with the NHS – si to 1.1 & 20 & si
journal advertising
     advertising in international journals – si to 1.1
     number of pages of – 6.3     
     specific requirements – 4.7 & 6
     see also abbreviated advertisements in professional
     publications – 5.2 & si

Back to top

K

‘knocking copy’ – 8.1 & si – see also 7.3

Back to top

L

labelling of:
     medicines – 1.2 under ‘It does not include’
     samples – 17.5
legislation – page 60
levy
     failure to pay – ¶ 16.6
     level of – ¶ 16.1
licensing authority, references to – 9.5
limitations on journal advertising – 6 & si
links to prescribing information – 4.4 & si
loans, long term or permanent – si to 18.1
loose inserts in journals – 6.2

Back to top

M

mailings
     frequency and number of – 11.2 & si
     mailed medicines – 17.10
     mailing lists – 11.3
margins – see trade practices
market extension – si to 1.1
market research – 12.2 & si
     disclosure of payments – 23.1 & si – 23.3 & si
     guidelines – The Legal & Ethical Guidelines for
     Healthcare Market Research – si to 12.2 & page 60
     revealing company responsible – si to 9.10
market share claims – si to 7
marketing authorization – 3 & si & si to 2
meals – limit on cost – 22.2 & si
media
     complaints arising from – ¶ 6
     relations with – 26 & si
medical and educational goods and services – 19 & si
medicine, definition – 1.3
medicines
     distributed in hospitals – si to 17.7
     handled by representatives – 17.7
     posted – 17.8
Medicines and Healthcare products Regulatory Agency
     case reports – ¶ 13.5
     complaints from – ¶ 9
     consultation with on:
          appointment of independent Appeal Board
          members – ¶ 3.1
          Code – ¶ 19.2
     Disease Awareness Campaigns Guidelines – si to
     26.2 & page 60
     MHRA Drug Safety Update – si to 9.5
     references to – 9.5 & si
     submission of:
        briefing material to – 15.9
        certificates to – 14.6
        names of signatories for promotional material
          to – 14.4
     The Blue Guide Advertising and Promotion of
          Medicines in the UK – si to 1.1, 28.1, 28.4 & 28.5
          & page 60
     yellow card scheme – 4.10 & 5.6
meetings – 22
     attendance by administrative staff – si to 22.1
     certification of meetings held outside the UK – 14.2
          & si
     continuing professional development (CPD)
          meetings and courses – si to 22.1
     exhibitions and exhibition panels, prescribing
          information requirements – si to 4.1
     held outside the UK – si to 22.1,
     hospitality, provision of – 22.1 & si
     involving travel outside the UK – si to 22.1,
          certification of – 14.2 & si
     organised by affiliates – si to 22.1
     payment of room rental – 22.3 & si     
     payment of travelling and accommodation expenses
          – 22 & si
     prohibition on inducements and payments for
          interviews – 15.3 & 18.1 & si
     promotion at international meetings – si to 3 & 22.1,
          see also si to 1.1
     reports on meetings – si to 22.4, see also 10.3     
     sponsorship of attendance at meetings, disclosure of
          – 22.5 & si
     sponsorship of meetings, disclosure of – 22.4 & si
     subsistence, provision of – 22.1 & si
     venue, suitability of – 22.1 & si
memory sticks for health professionals - si to 18.1
MHRA Drug Safety Update - si to 9.5

Back to top

N

naked or partially naked people, use of in advertising –
si to 9.1 & 9.2
new medicines
     advance notification of – si to 3.1
     format, size or cost of promotional material for – si
          to 9.7
     limitations on mailings – 11.2 & si
‘new’, use of the word – 7.11
non-interventional studies of marketed medicines –
13.2 to 13.4 & si
     approval and supervision of – 25.2
     disclosure of – 13.3 & si
non-proprietary name, size and position – 4.3 & 5.5
notebooks, pens and pencils – 18.3 & si
Nursing & Midwifery Council – Standards of conduct,
performance and ethics for nurses and midwives – si to
15.3, 18.1, 22.1 & page 60

Back to top

O

offence, causing – 9.2
official documents, reproduction of – 9.6
ordinary course sales and purchase of medicines – si to
   1.10
other relevant decision makers – definition – 1.5
outcome agreements – si to 18.1
over-the-counter medicines
     definition –  1.6
     scope of the Code – 1.1 & si

Back to top

P

package deals – si to 18.1
package leaflets – 1.2 under It does not include
     on the Internet – 28.5
     provision to the public – si to 26.2 & 28.5
Panel – see Code of Practice Panel
patient access schemes – si to 18.1
patient information leaflets
     provision by doctors to patients – 26.2 & 26.3 & si
     see also package leaflets
patient organisations
     disclosure of support for – 27.7 & si
     relationships with – 27 & si
     services provided by – 27.8 & si
patient safety – si to 2, see also ¶ 13.7
patient support items – 18.2 & si
payments for interviews – 15.3 & si & 18.1 & si
     unacceptable – si to 2, see also ¶ 13.7
pecuniary advantage, offer or provision of – 18.1 & si
personal benefits – 18.1 & si & 19.1 & 19.2 & si
pharmacovigilance – personnel’s knowledge of –  16.2
and si to 13
PMCPA guidance notes – page 60
post-authorization studies – 12.2 & 13
postcards, use of – 9.8
posted medicines – 17.8
post-marketing surveillance studies – 12.2 & 13
potency per weight claims – si to 7.2
pre-printed private prescription forms – si to 9.1 & 9.2
prescribing information
     general – 4
     date of – 4.2 & si
     exemptions – 4.1 & 5.1
     legibility – 4.1 & si
     provision on
          audio-visual etc – 4.5 & si
          exhibitions and exhibition panels – si to 4.1
          Internet – 4.6
          journal advertisements – 4.7
     requisite information – 4.2 & si
     size of non-proprietary name – 4.3
     typesize – si to 4.1
prescription forms
     pre-printed private prescription forms – si to 9.1 & 9.2
     reproduction of official documents –  9.6
Prescription Medicines Code of Practice Authority
     annual report – ¶ 20
     material to be supplied to Authority
          authority of Director to require material – ¶ 1.4
          copies of certificates – 14.6
          examination status of representatives – 16.4
          material required for scrutiny – ¶ 17.1
          medical representatives’ briefing material – 15.9
          names of signatories – 14.4
     scrutiny – ¶ 17
     structure and responsibilities – ¶ 1
press conferences and press announcements – 26.2 & si
pre-vetting
     cost of – ¶ 10.4 & ¶ 11.3
     power of Appeal Board to require – ¶ 10.4 & ¶ 11.3
price comparisons – si to 7.2
price lists – 1.2 under It does not include 
prices – see trade practices
private prescription forms, preprinted – si to 9.1 & 9.2
prizes – si to 18.1
professional publications – 5.2 & si for definition
promotion    
     definition – 1.2
     exemptions – 1.2 under ‘It does not include’
promotional aid
     definition – 1.8
     use of – 18.1 & si
provision of medicines and samples – control and
accountability – 17.9 si
public assessment reports (European & UK)
     exempt from the term ‘promotion’ – 1.2 under It does not include
     provision of
          on the Internet – 28.5
          to the public – si to 26.2 & 28.5 & si
public health campaigns – si to 26.2
public relations activities – 26 & si to 26.2
     responsibility for – 26.5
public, relations with
     advertising to – 1.1 & 26 & si
     disease awareness campaigns – si to 26.2
     enquiries from – 26.4 & si
     exposed mailings – 9.8 & si
     Internet – 28
     provision of information to – 26 & si, 28 & si
     provision of samples to – 17.9
     public health campaigns – si to 26.2

Back to top

Q

quizzes – si to 18.1
quotations – 10.2 & si, 10.3 & 10.4 & si see also 7.6

Back to top

R

referee, independent – ¶ 5.1, 5.2, 5.3, 7.2, 7.4, 7.5 & 7.6
references
     prohibition in abbreviated advertisements – 5.9
     references to published studies – 7.6 & si, 7.8 & si
relative risk, reference to – si to 7.2
remote detailing – si to 9.9
replies to individual enquiries – 1.2 under It does not include & si
reply paid cards – si to 9.8
     reply paid cards offering items to be delivered by
          representatives – si to 15.3
     see also samples, request forms – 17.3 & si
representatives
     general – 15
     briefing material – 15.9 & si
     contract representatives – si to 15
     definition – 1.7
     delivering items – si to 15.3
     examinations – 16.3 & si
     frequency & manner of calls on doctors – 15.4 & si
     hospitality and payments for meetings – si to 15.3
     identifying themselves – 15.5
     items delivered by representatives – si to 15.3
     prohibition on payments for interviews – 15.3 & si
     provision of summary of product characteristics
          by representatives – 15.8 & si
     reporting adverse reactions – 15.6
     training, general – 15.1, 16.1 & 16.3 & si
reprints of articles, distribution of – 10.1 & si
reproduction of official documents – 9.6
risk/benefit profile – si to 7.10
risk, relative and absolute – si to 7.2
risk sharing agreements – si to 18.1
room rental, payment – 22.3 & si
Royal College of Nursing
     case reports – ¶ 13.5
     consultation with on:
          appointment of independent Appeal Board
          member – ¶ 3.2
          Code – ¶ 19.2
Royal Pharmaceutical Society
     case reports – ¶ 13.5
     consultation with on:
          appointment of independent Appeal Board
          member – ¶ 3.2
          Code – ¶ 19.2
rulings by:
     Appeal Board – ¶ 10
     Panel – ¶ 7

Back to top

S

‘safe’, use of the word – 7.9 & si
samples – 17
     control and accountability of – 17.7
     definition – si to 17
     distribution
          in hospitals – si to 17.7
          to the public – 17.9
     identification samples – si to 17
     labelling – 17.5
     maximum number of – 17.2
     medicines not permitted as – 17.6
     medicines permitted as – 17.2 & si
     posted – 17.8
     request forms and their retention – 17.3 & si
     size – 17.4
     starter packs – si to 17
     titration packs – si to 17
     use as inducement – 17.10
     use for patient treatment – 17.10
sanctions
     advertisments in medical, pharmaceutical and
          nursing press – ¶ 13.7
     audit of company’s procedures – ¶ 10.4, ¶ 11.3 &
          ¶ 12.2
     breach of Clause 2 – ¶ 13.7
     case reports – ¶ 13
     corrective statements – ¶ 10.6, ¶ 11.3 & ¶ 13.7
     pre-vetting – ¶ 10.4 & ¶ 11.3
     recovery of items – ¶ 10.3 & ¶ 11.3
     reports to Appeal Board and ABPI Board – ¶ 8, ¶ 11
          & ¶ 12
     reprimand and publication – ¶ 10.5, ¶ 11.3 & ¶ 13.7 

     special provision for non ABPI companies – ¶ 11.4
          & ¶ 12.2
     suspension/expulsion from ABPI – ¶ 12.2 

     undertakings from companies ruled in breach –
          ¶ 7.1, 7.3 & ¶ 10.2
scientific services – 25
     to approve and supervise non-interventional studies
     – 25.2
     to compile and collate all information received
     – 25.1
scope of the Code – 1 & si
scrutiny – ¶ 17
Serious Fraud Office
     consultation with on Code – ¶ 19.2
sexual imagery, use of – si to 9.1 & 9.2
side-effects – see adverse reactions
signatories – 14 & si
size of promotional material
     abbreviated advertisements – 5.3
     extremes of format – 9.7 & si
sponsorship of material and meetings, disclosure of –
9.10 & si & 22.4 & si
sponsorship of meeting attendance, disclosure of – 22.5
& si
starter packs – si to 17
statistical information, use of – si to 7.2
     see also si to 7.8 on artwork, illustrations, graphs and
     tables
subsistence, provision of – 22.1 & si & 22.2 & si
substantiation of information, claims and comparisons
7.4 & 7.5
suitability and taste – 9.1 & 9.2 & si
summaries of product characteristics
     exempt from the term ‘promotion’ – 1.2 under It does not include
     provision of
          by representatives – 15.8 & si
          on the Internet – 28.5
          to the public – si to 26.2 & 28.5 & si
          with press releases and press packs – si to 26.2
          with samples – 17.5
          summary in prescribing information – 4.2 & si
superlatives – 7.10 & si
suspension of advertising on complaints from
Medicines and Healthcare products Regulatory Agency
– ¶ 9.2
suspension of material/activities required by Panel
pending appeal – ¶ 7.1 & ¶ 7.3
switch and therapy review programmes – si to 19.1
symposia – see meetings

Back to top

T

tables – see artwork, illustrations, graphs and tables
taste in advertising – si to 9.1 & 9.2
‘teaser’ advertising – si to 9.1 & 9.2
telemessages – 9.9 & si to 15   
telephone and text messages – 9.9 & si to 1​5
terms of trade – see trade practices
text messages – 9.9 & si to 15
textbooks, provision of – si to 18.1
'the', use of the word – si to 7.10
therapy review programmes – si to 19.1
timing under complaints procedure
     general – ¶ 14
     appeals – ¶ 7.3
     commenting on appeal by complainant – ¶ 7.4
     commenting on appeal by respondent – ¶ 7.5
     extensions – ¶ 7.1, ¶ 7.3 & ¶ 14
     payment of administrative charge – ¶ 7.1, ¶ 7.2,
          ¶ 10.1 & ¶ 10.2
     providing an undertaking on rulings by
          Appeal Board – ¶ 10.2
          Panel – ¶ 7.1 & ¶ 7.3
     responding to complaint – ¶ 5.4
     suspension of material/activities required by Panel
          pending appeal – ¶ 7.1 & ¶ 7.3
titration packs – si to 17
trade practices, prices, discounts, margins, etc – 1.2
under It does not include​​ and si to 18.1
training
     of representatives – 15.1, 16.1 & 16.3 & si
     on Code –  16.1 & si
transfers of value – 24
     central platform for disclosure – si to 24.1
     definition – 1.10 & si
     see disclosure of transfers of value –  1.10 & si, 24 & si
     excluded disclosures – si to  1.10
travelling expenses – 22 & si
two page journal advertisements – 6.1

Back to top

U

unauthorized medicines and unauthorized indications
3 & si – see also unlicensed medicines
undertakings by companies ruled in breach – ¶ 7.1,
7.3 & ¶ 10.2
undertakings, breach of – 29 and si to 2, see also ¶ 13.7
‘unique’, use of the word – si to 7.10
unlicensed medicines, price lists of – 1.2 & si

Back to top

V

volume of promotional material –  11.2 & si
voluntary admissions by pharmaceutical companies
– ¶ 5.6 &  16.4

Back to top

W

WHO Ethical Criteria for Medicinal Drug Promotion – see introduction to Code and page 60
withdrawal of complaints and appeals – ¶ 15
‘wraparounds’ on journals – si to 6.2
wrappers – 9.8

Back to top

XYX

yellow card scheme – 4.10 & 5.6

Back to top